Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Esophageal Varices
Interventions: endoscopic variceal band ligation; Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypertension, Mild Cognitive Impairment
Interventions: Mindfulness and DASH Diet Education, Education group; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 65 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension
Interventions: Self-Care Training; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 25 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
Interventions: standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet; Dietary Supplement
Lead sponsor: CAMC Health System; Other
Eligibility: 12 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) sustained release tablets, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
Interventions: This is observational IOP measurement; Device
Lead sponsor: Intuor Technologies, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Tucson, Arizona • Memphis, Tennessee

Conditions: Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospitalization, Traditional inpatient hospitalization; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Maternal Health Care, Hypertensive Disorder of Pregnancy
Interventions: Connected MOM +; Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertension Secondary to Kidney Transplant
Interventions: New Medication: Enalapril, Isradipine, Propranolol; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 5 Years to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Obesity, Cardiovascular Risk Factor
Interventions: Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Hypertension
Interventions: ALN-AGT01 RVR, Placebo, Zilebesiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Lake Forest, California • Tampa, Florida • Savannah, Georgia

Conditions: Glaucoma
Interventions: bevacizumab, balanced salt solution; Drug · Other
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obstructive Sleep Apnea
Interventions: Inspiratory muscle strength training, Placebo; Other
Lead sponsor: University of Arizona; Other
Eligibility: 30 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Nephropathy
Interventions: Lisinopril, Nifedipine, Simvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1999
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Weight Loss Trial, Cardiometabolic Syndrome, Hypertension, Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus
Interventions: Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Springdale, Arkansas • Honolulu, Hawaii

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Tadalafil- Tablet or Oral suspension; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Metabolic Syndrome, Diabetes, Prediabetes, Hypertension
Interventions: Not listed
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Conditions: Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Interventions: ONO-9054, Placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 3
States / cities: Costa Mesa, California • Newport Beach, California • Santa Ana, California

Conditions: Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome, Pseudoexfoliation Glaucoma
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Eye Diseases, Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions: Auto-aligned OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 1 Month and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Liver Diseases, Portal Hypertension
Interventions: SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Vision Disorder
Interventions: Virtual Reality Stimulation; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding

Brain Connections and Blood Pressure

FSU Hypertension Self-Care Training Study

A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS

Hospital-Level Care at Home for Acutely Ill Adults

Implementation Models for Blood Pressure Monitoring in Pregnancy and Postpartum: Connected MOM Plus

Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

Coordinating Pragmatic Primary Care Population Management for Obesity

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

Inspiratory Muscle Strength Training for Sleep-related Breathing Disorders

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

Peau o le Vasa: Analysis of the Efficacy and Feasibility of the PILI Lifestyle Program (PLP) + Social Determinants of Health (SDOH) Intervention and Adaptation of SDOH Measures Pilot Study

Prediction of Expected Length of Hospital Stay Using Machine Learning

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Biomarkers of Metabolic Syndrome and Prediabetes

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

Virtual Reality for Enhancement of Vision